Home / Research library / Semaglutide
Semaglutide: molecular data, studies & sources
Semaglutide is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C187H291N45O59
- Molecular weight (MW)
- 4114 g/mol
- PubChem compound ID
- 56843331
- Record title
- Semaglutide
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 56843331 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
- InChIKey
- DLSWIYLPEUIQAV-CCUURXOWSA-N
- SMILES
- CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
Identifiers
- PubChem CID
- 56843331
- CAS Registry Number
- 910463-68-2via ChemIDplus, EPA DSSTox, FDA GSRS
- FDA UNII
- 53AXN4NNHX
- ChEMBL ID
- CHEMBL2108724
- InChIKey
- DLSWIYLPEUIQAV-CCUURXOWSA-N
- Wikidata
- Q27261089
Other names and development codes: NN-9535 · NNC 0113-0217
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 4111.1154 Da |
|---|---|
| Heavy atoms | 291 |
| Hydrogen-bond donors | 57 |
| Hydrogen-bond acceptors | 56 |
| Rotatable bonds | 149 |
| Topological polar surface area | 1646.2 Ų |
| Calculated logP (Crippen) | -11.63 |
| Rings | 6 |
| Stereocenters | 30 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Semaglutide is the active ingredient of FDA-approved medicines that Drugs@FDA lists as marketed prescription products (checked October 7, 2026): OZEMPIC (NDA 209637, approved December 5, 2017), OZEMPIC / RYBELSUS (NDA 213051, approved September 20, 2019), RYBELSUS (NDA 213182, approved January 16, 2020) and WEGOVY (NDA 215256, approved June 4, 2021; NDA 218316, approved December 22, 2025). Research-labelled Semaglutide listings are not OZEMPIC, RYBELSUS or WEGOVY and are not FDA-approved drugs.
| Medicine | Application | Sponsor | First approval | Marketing status |
|---|---|---|---|---|
| OZEMPICsemaglutide | NDA 209637DailyMed label: Ozempic · 2026-07-30DailyMed label: Ozempic · 2023-11-22 | NOVO | Discontinued · Prescription | |
| OZEMPIC / RYBELSUSsemaglutide | NDA 213051DailyMed label: OZEMPIC · 2026-01-30 | NOVO | Prescription | |
| RYBELSUSsemaglutide | NDA 213182 | NOVO NORDISK INC | Prescription | |
| WEGOVYsemaglutide | NDA 215256DailyMed label: WEGOVY · 2024-04-23 | NOVO | Prescription | |
| WEGOVYsemaglutide | NDA 218316 | NOVO | Prescription |
An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: Same active ingredient name (semaglutide). FDA separately warns that semaglutide sodium and semaglutide acetate are different from the active ingredient in approved products.
Source: Drugs@FDA via openFDA (application records; DailyMed label set IDs) · checked . openFDA data are not intended for clinical decisions.
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL2108724
- Modality
- Protein / peptide
- Highest clinical stage
- Approved in at least one jurisdiction (ChEMBL phase 4)
- Record name
- SEMAGLUTIDE
Mechanism of action
- Glucagon-like peptide 1 receptor agonist · target: Glucagon-like peptide 1 receptor (GLP1R)
Synonyms, codes and trade names
- Trade and brand names (Drugs@FDA)
- OZEMPIC · RYBELSUS · WEGOVY · WEGOVY FLEXTOUCH · WEGOVY HD
- Synonyms and development codes
- NN-9535 · NN9535 · NNC 0113-0217 · NNC-0113-0217 · Semaglutide
Identity check: PubChem / GSRS ChEMBL cross-reference and an exact name match. Source: ChEMBL CHEMBL2108724 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Semaglutide as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
34 registered studies matched, 34 currently active or recruiting.
- By highest phase
- Phase 4 · 8Phase 3 · 12Phase 2 · 2Phase 1 · 2Early phase 1 · 1Not applicable · 9
- By registry status
- Recruiting · 20Not Yet Recruiting · 11Active Not Recruiting · 2Enrolling By Invitation · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)NCT07586150 · start 2028-10 · primary completion 2030-07 | Not applicableNot Yet Recruiting | Severe Mental Illness · Depression / Major Depressive Disorder · Bipolar Disorder (BD) · Schizophrenia | Ludwig-Maximilians - University of Munich140 participants |
| Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes MellitusNCT07797036 · start 2027-09-01 · primary completion 2030-09-01 | Phase 2 / Phase 3Not Yet Recruiting | Gestational Diabetes Mellitus (GDM) · Metabolic Syndrome | University of Massachusetts, Worcester226 participants |
| Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic SyndromeNCT07770282 · start 2026-12-01 · primary completion 2030-07-30 | Phase 3Not Yet Recruiting | Schizophrenia Disorder · Metabolic Syndrome · Antipsychotic-induced Weight Gain · Cardiovascular Risk · Insulin Resistance | All India Institute of Medical Sciences, Bhubaneswar600 participants |
| GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver DiseaseNCT06546384 · start 2026-11-01 · primary completion 2026-12-31 | Not applicableNot Yet Recruiting | Adiposity · Fatty Liver · Alcohol Use Disorder | Insel Gruppe AG, University Hospital Bern64 participants |
| SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 YearsNCT07845994 · start 2026-11 · primary completion 2031-02 | Phase 3Not Yet Recruiting | Craniopharyngioma, Child | University Hospital, Angers50 participants |
| GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular CancerNCT07627191 · start 2026-10-10 · primary completion 2028-06-30 | Early phase 1Recruiting | Pancreatic Cancer · Colorectal Cancer · Hepatocellular Carcinoma | University of Arizona30 participants |
| BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or ObesityNCT07622810 · start 2026-09 · primary completion 2027-12 | Phase 3Not Yet Recruiting | Obesity & Overweight | Carnot Laboratories352 participants |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · start 2026-08-04 · primary completion 2029-09-07 | Phase 3Recruiting | Diabetes Mellitus, Type 2 | Novo Nordisk A/S80 participants |
| Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)NCT07218354 · start 2026-07-28 · primary completion 2029-03-31 | Phase 3Recruiting | Alcohol Use Disorder | VA Office of Research and Development622 participants |
| Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction TendenciesNCT07732426 · start 2026-07-15 · primary completion 2028-02-29 | Not applicableRecruiting | Food Addiction Tendency · Obesity · Overweight | Seoul National University Hospital30 participants |
Show 24 more registered studies
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With ObesityNCT07728383 · start 2026-06-17 · primary completion 2027-05 | Phase 4Recruiting | Obesity & Overweight | Gila Therapeutics, Inc.40 participants |
| Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 · start 2026-04-10 · primary completion 2028-04-28 | Phase 1Recruiting | Obesity | Novo Nordisk A/S100 participants |
| Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 DiabetesNCT07599046 · start 2026-04-30 · primary completion 2027-01-30 | Not applicableNot Yet Recruiting | Obesity Type 2 Diabetes Mellitus | Eighth Affiliated Hospital, Sun Yat-sen University20 participants |
| Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthNCT06975111 · start 2026-03-01 · primary completion 2029-10-31 | Phase 2 / Phase 3Recruiting | Menopause · Menopause Hot Flashes · Menopause Related Conditions · Cardiovascular | University of Colorado, Denver200 participants |
| Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)NCT07223983 · start 2026-03-26 · primary completion 2027-02 | Phase 1Active Not Recruiting | Alcohol Use Disorder · Weight Loss · Bariatric Surgery Patients | Yale University4 participants |
| Waiting on Atrial Fibrillation Intervention Therapy (WAIT) StudyNCT07275697 · start 2026-03-23 · primary completion 2028-12-30 | Phase 4Recruiting | Atrial Fibrillation (AF) · Obesity & Overweight | Emma Svennberg200 participants |
| Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic OutcomesNCT07424430 · start 2026-03 · primary completion 2026-04 | Not applicableNot Yet Recruiting | Diabetes (DM) · Type 2 Diabetes · Obesity (Disorder) | LMC Diabetes & Endocrinology Ltd.400 participants |
| DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot StudiesNCT07483801 · start 2026-03 · primary completion 2027-04 | Phase 4Not Yet Recruiting | Cardiovascular Diseases | Cambridge University Hospitals NHS Foundation Trust112 participants |
| Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide TerminationNCT07294950 · start 2026-02-01 · primary completion 2028-09 | Phase 3Recruiting | Obesity (Disorder) · Weight Change · Blood Pressure Monitoring · Appetite Regulation | Mount Sinai Hospital, Canada98 participants |
| Individualized Pharmacological Approach to Obesity in Patients With Bipolar DisorderNCT07213466 · start 2026-01-19 · primary completion 2028-02-01 | Phase 4Recruiting | Bipolar I Disorder · Bipolar II Disorder · Schizo Affective Disorder · Obesity · Weight Loss · GLP - 1 | Mayo Clinic100 participants |
| Repurposing Semaglutide for the Treatment of Cocaine Use DisorderNCT07227948 · start 2026-01-15 · primary completion 2029-01-28 | Phase 2Recruiting | Cocaine Use Disorder | The University of Texas Health Science Center, Houston75 participants |
| OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management ProgrammeNCT07779343 · start 2026-01-22 · primary completion 2028-01-23 | Not applicableRecruiting | Obesity Difficult Airway Airway Management · Obesity Adult Onset · Obesity and Cardiovascular Risk · Obesity Type 2 Diabetes Mellitus | University of Health Sciences, Algeria300 participants |
| Semaglutide Treatment in Type 1 DiabetesNCT06909006 · start 2025-10 · primary completion 2028-06 | Phase 3Not Yet Recruiting | Obesity in Diabetes · Obesity/Therapy · Type 1 Diabetes Mellitus (T1DM) · Insulin Sensitivity/Resistance · Semaglutide · Lipidomics | Nordsjaellands Hospital122 participants |
| Rebalancing the Fat Content of the Heart and MusclesNCT07065383 · start 2025-08-01 · primary completion 2028-07-31 | Not applicableRecruiting | Diabetes Mellitus Type 2 | University of Aberdeen60 participants |
| Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With ObesityNCT07091500 · start 2025-08-11 · primary completion 2028-08-01 | Not applicableRecruiting | Obesity · Skeletal Muscle · Brain Connectivity | Washington University School of Medicine40 participants |
| A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 DiabetesNCT07139548 · start 2025-08-31 · primary completion 2026-12-01 | Phase 3Not Yet Recruiting | T2DM | Guangdong Raynovent Biotech Co., Ltd600 participants |
| Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation TherapyNCT06908694 · start 2025-07-02 · primary completion 2027-10-31 | Phase 4Active Not Recruiting | Prostate Cancer | Hamilton Health Sciences Corporation20 participants |
| Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetesNCT07254572 · start 2025-07-10 · primary completion 2029-08-01 | Phase 4Recruiting | Coronary Artery Disease · PreDiabetes | National Institute of Cardiology, Warsaw, Poland300 participants |
| JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With ObesityNCT06852391 · start 2025-06-18 · primary completion 2027-12-31 | Phase 4Recruiting | Obesity (Disorder) | McMaster University74 participants |
| Protein Supplementation Intervention on Body WeightNCT06989203 · start 2025-06-10 · primary completion 2026-12-31 | Not applicableRecruiting | Obesity · Weight Loss · Protein Supplementation | Chinese Academy of Sciences140 participants |
| Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes MellitusNCT07374328 · start 2025-06-01 · primary completion 2026-05-31 | Phase 1 / Phase 2Recruiting | Type 2 Diabetes | Second Affiliated Hospital of Guangzhou Medical University240 participants |
| Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal WomenNCT07057310 · start 2025-05-01 · primary completion 2026-12-31 | Phase 4Enrolling By Invitation | Obesity · Menopause | Mayo Clinic30 participants |
| Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial FibrillationNCT06499857 · start 2025-04-14 · primary completion 2027-12 | Phase 3Recruiting | Overweight or Obesity · Atrial Fibrillation | University of Chicago200 participants |
| Effect of Semaglutide in Patients With Psoriasis and ObesityNCT06937060 · start 2025-03-20 · primary completion 2026-07-31 | Phase 3Recruiting | Psoriasis (PsO) · Obesity and Overweight | The University of Hong Kong14 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Semaglutide, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK et al. · The New England journal of medicine · 2025
PMID 40544433 · DOI: 10.1056/NEJMoa2502081
- Human study · PubMed trial index Compound given to participants
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M et al. · Diabetes, obesity & metabolism · 2022
PMID 35441470 · DOI: 10.1111/dom.14725
- Human study · PubMed trial index Compound given to participants
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A et al. · The New England journal of medicine · 2016
PMID 27633186 · DOI: 10.1056/NEJMoa1607141
- Human study · PubMed trial index Compound given to participants
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S et al. · The New England journal of medicine · 2021
PMID 33567185 · DOI: 10.1056/NEJMoa2032183
- Human study · PubMed trial index Compound given to participants
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M et al. · JAMA · 2021
PMID 33755728 · DOI: 10.1001/jama.2021.3224
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Review · secondary evidence
Safety of Semaglutide.
Smits MM, Van Raalte DH · Frontiers in endocrinology · 2021
PMID 34305810 · DOI: 10.3389/fendo.2021.645563
- Review · secondary evidence
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Dampil OA, Marquez MM et al. · Journal of the ASEAN Federation of Endocrine Societies · 2022
PMID 36578889 · DOI: 10.15605/jafes.037.02.14
- Preclinical / laboratory research
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery S, Salinas CG, Paulsen SJ et al. · JCI insight · 2020
PMID 32213703 · DOI: 10.1172/jci.insight.133429
Semaglutide supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Semaglutide for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| American PeptidesUSD | 5mg Vial · 10mg Vial · 20mg Vial · 30mg Vial · 50mg Vial5 recorded offers | 5mg Vial · $60.00Checked Nov 6, 2026Supplier listing, Semaglutide 5mg Vial, American Peptides, opens in a new tab |
| Blank PeptidesUSD | 10mg Vial1 recorded offers | 10mg Vial · $79.00Stale observation · Checked Sep 30, 2026Supplier listing, Semaglutide 10mg Vial, Blank Peptides, opens in a new tab |
| Amino ClubUSD | 10mg Vial1 recorded offers | 10mg Vial · $49.99Stale observation · Checked Oct 14, 2026Supplier listing, Semaglutide 10mg Vial, Amino Club, opens in a new tab |
| Nova Peptide SupplyUSD | 10mg Vial1 recorded offers | 10mg Vial · $79.99Checked Nov 6, 2026Supplier listing, Semaglutide 10mg Vial, Nova Peptide Supply, opens in a new tab |
| LA PeptidesUSD | 5mg Vial · 10mg Vial2 recorded offers | 5mg Vial · $64.99Checked Nov 3, 2026Supplier listing, Semaglutide 5mg Vial, LA Peptides, opens in a new tab |
Reference sources & further reading
- PubChem compound record 56843331 — chemical identity and structure.
- ChEMBL drug record CHEMBL2108724 — development stage, mechanism and synonyms.
- FDA Global Substance Registration System: UNII 53AXN4NNHX — substance identity, names and codes.
- Drugs@FDA: NDA 209637 — US approval record for a medicine with the same active ingredient.
- Drugs@FDA: NDA 213051 — US approval record for a medicine with the same active ingredient.
- Drugs@FDA: NDA 213182 — US approval record for a medicine with the same active ingredient.
- Drugs@FDA: NDA 215256 — US approval record for a medicine with the same active ingredient.
- Drugs@FDA: NDA 218316 — US approval record for a medicine with the same active ingredient.
- Wikipedia: Semaglutide — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Cagrilintide
C194H312N54O59S2
4409 g/mol · PubChem CID 171397054
5 selected publications · 4 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Eloralintide
Molecular identity needs further verification
4 selected publications · 3 human intervention studies · 22 registered trials
Liraglutide
C172H265N43O51
3751 g/mol · PubChem CID 16134956
7 selected publications · 4 human intervention studies · 33 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Mazdutide
C207H317N45O65
4476 g/mol · PubChem CID 167312357
7 selected publications · 6 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Orforglipron Capsules
C48H48F2N10O5
883.0 g/mol · PubChem CID 137319706
8 selected publications · 6 human intervention studies · 40 registered trials
Small molecule · highest stage: Phase 3
Retatrutide
C221H342N46O68
4731 g/mol · PubChem CID 171390338
9 selected publications · 7 human intervention studies · 34 registered trials